1. Lacroix, A, Feelders, RA, Stratakis, CA, Nieman, LK. Cushing’s syndrome. Lancet. 2015;386:913-927.
Google Scholar | Crossref | Medline2. Geer, EB, Shafiq, I, Gordon, MB, et al. Biochemical control during long-term follow-up of 230 adult patients with Cushing disease: a multicenter retrospective study. Endocr Pract. 2017;23:962-970.
Google Scholar | Crossref | Medline3. Papakokkinou, E, Olsson, DS, Chantzichristos, D, et al. Excess morbidity persists in patients with Cushing’s disease during long-term remission: a Swedish nationwide study. J Clin Endocrinol Metab. 2020;105:2616-2624.
Google Scholar | Crossref4. Pivonello, R, Isidori, AM, De Martino, MC, Newell-Price, J, Biller, BM, Colao, A. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4:611-629.
Google Scholar | Crossref | Medline5. Howlett, TA, Drury, PL, Perry, L, Doniach, I, Rees, LH, Besser, GM. Diagnosis and management of ACTH-dependent Cushing’s syndrome: comparison of the features in ectopic and pituitary ACTH production. Clin Endocrinol (Oxf). 1986;24:699-713.
Google Scholar | Crossref | Medline | ISI6. Friedman, TC, Ghods, DE, Shahinian, HK, et al. High prevalence of normal tests assessing hypercortisolism in subjects with mild and episodic Cushing’s syndrome suggests that the paradigm for diagnosis and exclusion of Cushing’s syndrome requires multiple testing. Horm Metab Res. 2010;42:874-881.
Google Scholar | Crossref | Medline | ISI7. Kidambi, S, Raff, H, Findling, JW. Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing’s syndrome. Eur J Endocrinol. 2007;157:725-731.
Google Scholar | Crossref | Medline | ISI8. Kreitschmann-Andermahr, I, Psaras, T, Tsiogka, M, et al. From first symptoms to final diagnosis of Cushing’s disease: experiences of 176 patients. Eur J Endocrinol. 2015;172:285-289.
Google Scholar | Crossref | Medline9. Nieman, LK, Biller, BM, Findling, JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526-1540.
Google Scholar | Crossref | Medline | ISI10. Fleseriu, M, Hamrahian, AH, Hoffman, AR, Kelly, DF, Katznelson, L, AACE Neuroendocrine and Pituitary Scientific Committee. American Association of Clinical Endocrinologists and American College Of Endocrinology disease state clinical review: diagnosis of recurrence in Cushing disease. Endocr Pract. 2016;22:1436-1448.
Google Scholar | Crossref | Medline11. Nieman, LK, Biller, BM, Findling, JW, et al. Treatment of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:2807-2831.
Google Scholar | Crossref | Medline | ISI12. Braun, LT, Rubinstein, G, Zopp, S, et al. Recurrence after pituitary surgery in adult Cushing’s disease: a systematic review on diagnosis and treatment. Endocrine. 2020;70:218-231.
Google Scholar | Crossref | Medline13. Pivonello, R, De Leo, M, Cozzolino, A, Colao, A. The treatment of Cushing’s disease. Endocr Rev. 2015;36:385-486.
Google Scholar | Crossref | Medline | ISI14. Patil, CG, Prevedello, DM, Lad, SP, et al. Late recurrences of Cushing’s disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab. 2008;93:358-362.
Google Scholar | Crossref | Medline15. Ciric, I, Zhao, JC, Du, H, et al. Transsphenoidal surgery for Cushing disease: experience with 136 patients. Neurosurgery. 2012;70:70-80.
Google Scholar | Crossref | Medline16. Pivonello, R, Ferrigno, R, Isidori, AM, Biller, BMK, Grossman, AB, Colao, A. COVID-19 and Cushing’s syndrome: recommendations for a special population with endogenous glucocorticoid excess. Lancet Diabetes Endocrinol. 2020;8:654-656.
Google Scholar | Crossref | Medline17. Newell-Price, J, Nieman, LK, Reincke, M, Tabarin, A. Endocrinology in the time of COVID-19: management of Cushing’s syndrome. Eur J Endocrinol. 2020;183:G1.
Google Scholar | Crossref | Medline18. Fleseriu, M, Buchfelder, M, Cetas, JS, et al. Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic-an international perspective. Pituitary. 2020;23:327-337.
Google Scholar | Crossref | Medline19. Loeffler, JS, Shih, HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab. 2011;96:1992-2003.
Google Scholar | Crossref | Medline20. Hamrahian, AH, Yuen, KCJ, Hoffman, AR, AACE Neuroendocrine and Pituitary Scientific Committee. AACE/ACE disease state clinical review: medical management of Cushing disease. Endocr Pract. 2014;20:746-757.
Google Scholar | Crossref | Medline21. Sundaram, NK, Carluccio, A, Geer, EB. Characterization of persistent and recurrent Cushing’s disease. Pituitary. 2014;17:381-391.
Google Scholar | Crossref | Medline22. Guarnotta, V, Ferrigno, R, Martino, M, et al. Glucocorticoid excess and COVID-19 disease. Rev Endocr Metab Disord. Published online October 6, 2020. doi:10.1007/s11154-020-09598-x
Google Scholar23. KORLYM ® (mifepristone) 300 mg Tablets [prescribing information] . Corcept Therapeutics Incorporated; November 2019.
Google Scholar24. Fleseriu, M, Biller, BM, Findling, JW, Molitch, ME, Schteingart, DE, Gross, C. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab. 2012;97:2039-2049.
Google Scholar | Crossref | Medline | ISI25. Ragnarsson, O. Cushing’s syndrome ‒ disease monitoring: recurrence, surveillance with biomarkers or imaging studies. Best Pract Res Clin Endocrinol Metab. 2020;34:101382.
Google Scholar | Crossref | Medline26. Spark, RF, Melby, JC. Aldosteronism in hypertension. The spironolactone response test. Ann Intern Med. 1968;69:685-691.
Google Scholar | Crossref | Medline | ISI27. Ross, DS, Burch, HB, Cooper, DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343-1421.
Google Scholar | Crossref | Medline | ISI28. Javanmard, P, Duan, D, Geer, EB. Mortality in patients with endogenous Cushing’s syndrome. Endocrinol Metab Clin North Am. 2018;47:313-333.
Google Scholar | Crossref | Medline29. Dekkers, OM, Horváth-Puhó, E, Jorgensen, JO, et al. Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J Clin Endocrinol Metab. 2013;98:2277-2284.
Google Scholar | Crossref | Medline | ISI30. Hassan-Smith, ZK, Sherlock, M, Reulen, RC, et al. Outcome of Cushing’s disease following transsphenoidal surgery in a single center over 20 years. J Clin Endocrinol Metab. 2012;97:1194-1201.
Google Scholar | Crossref | Medline31. Ntali, G, Asimakopoulou, A, Siamatras, T, et al. Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol. 2013;169:715-723.
Google Scholar | Crossref | Medline32. Pivonello, R, De Martino, MC, De Leo, M, Simeoli, C, Colao, A. Cushing’s disease: the burden of illness. Endocrine. 2017;56:10-18.
Google Scholar | Crossref | Medline33. Hasenmajer, V, Sbardella, E, Sciarra, F, Minnetti, M, Isidori, AM, Venneri, MA. The immune system in Cushing’s syndrome. Trends Endocrinol Metab. 2020;31:655-669.
Google Scholar | Crossref | Medline34. Valassi, E, Franz, H, Brue, T, et al. Preoperative medical treatment in Cushing’s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. Eur J Endocrinol. 2018;178:399-409.
Google Scholar | Crossref | Medline35. Cohan, P, East, HE, Galati, SJ, et al. Mifepristone treatment in four cases of primary bilateral macronodular adrenal hyperplasia (BMAH). J Clin Endocrinol Metab. 2019;104:6279-6290.
Google Scholar | Crossref | Medline36. Saroka, RM, Kane, MP, Robinson, L, Busch, RS. No postoperative adrenal insufficiency in a patient with unilateral cortisol-secreting adenomas treated with mifepristone before surgery. Clin Med Insights Endocrinol Diabetes. 2016;9:31-36.
Google Scholar | SAGE Journals37. Magaji, V, Park, SY, Mastoris, K, Bucciarelli, M, Beman, S. Mifepristone utilization in Cushing’s from large bilateral adrenal adenoma prior to surgery. J Endocrinol Metab. 2015;5:226-228.
Google Scholar | Crossref | ISI38. Fleseriu, M, Findling, JW, Koch, CA, Schlaffer, S-M, Buchfelder, M, Gross, C. Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing’s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone. J Clin Endocrinol Metab. 2014;99:3718-3727.
Google Scholar | Crossref | Medline | ISI39. Mehta, GU, Ding, D, Patibandla, MR, et al. Stereotactic radiosurgery for Cushing disease: results of an international, multicenter study. J Clin Endocrinol Metab. 2017;102:4284-4291.
Google Scholar | Crossref | Medline40. Estrada, J, Boronat, M, Mielgo, M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. N Engl J Med. 1997;336:172-177.
Google Scholar | Crossref | Medline41. Minniti, G, Osti, M, Jaffrain-Rea, ML, Esposito, V, Cantore, G, Maurizi Enrici, R. Long-term follow-up results of postoperative radiation therapy for Cushing’s disease. J Neurooncol. 2007;84:79-84.
Google Scholar | Crossref | Medline42. Brown, DR, East, HE, Eilerman, BS, et al. Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations. Clin Diabetes Endocrinol. 2020;6:18.
Google Scholar | Crossref | Medline43. Guarda, FJ, Findling, J, Yuen, KCJ, Fleseriu, M, Nachtigall, LB. Mifepristone increases thyroid hormone requirements in patients with central hypothyroidism: a multicenter study. J Endocr Soc. 2019;3:1707-1714.
Google Scholar | Crossref | Medline